BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37355557)

  • 1. Engineering Cell Lines for Specific Human Leukocyte Antigen Presentation.
    Jin D; Loh KL; Shamekhi T; Ting YT; Lim Kam Sian TCC; Roest J; Ooi JD; Vivian JP; Faridi P
    Methods Mol Biol; 2023; 2691():351-369. PubMed ID: 37355557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
    Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
    Front Immunol; 2018; 9():912. PubMed ID: 29780384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells.
    Lee MN; Meyerson M
    Sci Immunol; 2021 Jan; 6(55):. PubMed ID: 33483338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles.
    Hensen L; Illing PT; Rowntree LC; Davies J; Miller A; Tong SYC; Habel JR; van de Sandt CE; Flanagan KL; Purcell AW; Kedzierska K; Clemens EB
    Front Immunol; 2022; 13():812393. PubMed ID: 35603215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOF
    Hoenisch Gravel N; Nelde A; Bauer J; Mühlenbruch L; Schroeder SM; Neidert MC; Scheid J; Lemke S; Dubbelaar ML; Wacker M; Dengler A; Klein R; Mauz PS; Löwenheim H; Hauri-Hohl M; Martin R; Hennenlotter J; Stenzl A; Heitmann JS; Salih HR; Rammensee HG; Walz JS
    Nat Commun; 2023 Nov; 14(1):7472. PubMed ID: 37978195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
    Gloger A; Ritz D; Fugmann T; Neri D
    Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
    Kissick HT; Sanda MG; Dunn LK; Arredouani MS
    PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens.
    Forlani G; Michaux J; Pak H; Huber F; Marie Joseph EL; Ramia E; Stevenson BJ; Linnebacher M; Accolla RS; Bassani-Sternberg M
    Mol Cell Proteomics; 2021; 20():100032. PubMed ID: 33592498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
    Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
    Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
    ElAbd H; Franke A
    Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FASTMAP-a flexible and scalable immunopeptidomics pipeline for HLA- and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells.
    Weisbrod L; Capriotti L; Hofmann M; Spieler V; Dersch H; Voedisch B; Schmidt P; Knake S
    Front Immunol; 2024; 15():1386160. PubMed ID: 38779658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Neoantigen Discovery Using Large-Scale Immunopeptidomes and Composite Modeling of MHC Peptide Presentation.
    Pyke RM; Mellacheruvu D; Dea S; Abbott C; Zhang SV; Phillips NA; Harris J; Bartha G; Desai S; McClory R; West J; Snyder MP; Chen R; Boyle SM
    Mol Cell Proteomics; 2023 Apr; 22(4):100506. PubMed ID: 36796642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics.
    Lim Kam Sian TCC; Goncalves G; Steele JR; Shamekhi T; Bramberger L; Jin D; Shahbazy M; Purcell AW; Ramarathinam S; Stoychev S; Faridi P
    Front Immunol; 2023; 14():1107576. PubMed ID: 37334365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection.
    Augusto DG; Hollenbach JA
    Curr Opin Immunol; 2022 Jun; 76():102178. PubMed ID: 35462277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope distribution in ordered and disordered protein regions - part A. T-cell epitope frequency, affinity and hydropathy.
    Mitić NS; Pavlović MD; Jandrlić DR
    J Immunol Methods; 2014 Apr; 406():83-103. PubMed ID: 24614036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCR alpha genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope.
    Miles JJ; Borg NA; Brennan RM; Tynan FE; Kjer-Nielsen L; Silins SL; Bell MJ; Burrows JM; McCluskey J; Rossjohn J; Burrows SR
    J Immunol; 2006 Nov; 177(10):6804-14. PubMed ID: 17082594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
    Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
    Front Immunol; 2021; 12():645770. PubMed ID: 33968037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.